PPCB: financial statements from SEC — TradeAlmanac

PPCB

Propanc Biopharma, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Research and development	169,660	19,961	60,201	54,097	54,388	61,714
Selling, general and administrative	6M	4M	5M	53M	153,593	220,759
Operating expenses	6M	4M	5M	53M	213,382	290,790
Operating income	−6M	−4M	−5M	−53M	−213,382	−290,790
Pre-tax income	−6M	−3M	−5M	−54M	−430,183	−354,310
Net income	−6M	−3M	−5M	−54M	−430,183	−354,310
Earnings per share	−0.28	−0.30	−0.39	−12.50	−32.23	−35.97
Earnings per share, diluted	−0.28	−0.30	−0.39	−12.50	−32.23	−35.97
Weighted average shares	22M	13M	12M	4M	13,347	9,849
Weighted average shares, diluted	22M	13M	12M	4M	13,347	9,849

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Current assets	8M	8M	9M	8M	10M	17,984	21,534	25,441
Property, plant and equipment	4,221	4,397

Cash flow

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	30/09/2024
Operating cash flow	—	—	−2M	—	−235,515
Depreciation and amortisation	316	229	125	0	—
Share-based compensation

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator